MCID: MTR002
MIFTS: 51

Mitral Valve Insufficiency

Categories: Cardiovascular diseases

Aliases & Classifications for Mitral Valve Insufficiency

MalaCards integrated aliases for Mitral Valve Insufficiency:

Name: Mitral Valve Insufficiency 12 44 15 70
Mitral Regurgitation 12 29 54 6 15
Congenital Insufficiency of Mitral Valve 12 70
Congenital Mitral Insufficiency 12 32
Congenital Mitral Regurgitation 12
Mitral Valve Incompetence 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11502
ICD9CM 34 396.3 746.6
MeSH 44 D008944
NCIt 50 C50888
ICD10 32 Q23.3
UMLS 70 C0026266 C0158619 C0264774

Summaries for Mitral Valve Insufficiency

MalaCards based summary : Mitral Valve Insufficiency, also known as mitral regurgitation, is related to inferior myocardial infarction and atrial standstill 1. An important gene associated with Mitral Valve Insufficiency is TBX5 (T-Box Transcription Factor 5), and among its related pathways/superpathways are cGMP-PKG signaling pathway and Cardiac conduction. The drugs Ranolazine and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Mitral Valve Insufficiency

Diseases in the Mitral Valve Disease family:

Mitral Valve Insufficiency

Diseases related to Mitral Valve Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 563)
# Related Disease Score Top Affiliating Genes
1 inferior myocardial infarction 31.4 TNNI3 NPPB ACE
2 atrial standstill 1 31.3 TNNT2 TNNI3 NPPB MYH6 MYBPC3 ACE
3 atrioventricular block 31.2 TNNI3 TBX5 NPPB ACE
4 rheumatic fever 31.1 NPPB ALB ACE
5 systolic heart failure 31.1 NR3C2 NPPB NPPA CRP ACE
6 pulmonary hypertension 31.1 REN NPPB NPPA F2 CRP ALB
7 aortic aneurysm 30.9 NDE1 MYH11 FBN1 ACE
8 angina pectoris 30.8 TNNI3 NPPB CRP ACE
9 coronary stenosis 30.8 TNNI3 NPPB CRP ALB ACE
10 aortic valve disease 1 30.8 TBX5 REN MYH6 MYH11 FBN1 ACE
11 endocarditis 30.8 TNNI3 F2 CRP ALB
12 aortic dissection 30.7 NDE1 MYH11 FBN1 CRP ACE
13 atrial fibrillation 30.7 TBX5 NR3C2 NPPB NPPA MYBPC3 F2
14 hemopericardium 30.7 TNNI3 FBN1 F2 CRP
15 infective endocarditis 30.7 TNNT2 TNNI3 F2 CRP
16 lateral myocardial infarction 30.7 TNNI3 NR3C2 ACE
17 mitral valve stenosis 30.6 REN NPPB NPPA F2 CRP ACE
18 left bundle branch hemiblock 30.6 TNNT2 TNNI3 REN NR3C2 NPPB CRP
19 anterolateral myocardial infarction 30.6 NPPB NPPA ACE
20 coronary artery vasospasm 30.6 TNNI3 REN CRP ACE
21 intermediate coronary syndrome 30.6 TNNT2 TNNI3 REN MIR423 CRP ACE
22 congestive heart failure 30.5 TNNT2 TNNI3 REN NR3C2 NPPB NPPA
23 amyloidosis 30.5 TNNT2 TNNI3 NPPB CRP ALB
24 peripheral vascular disease 30.5 F2 CRP ALB ACE
25 purpura 30.5 F2 CRP ACE
26 orthostatic intolerance 30.5 REN MYH11 MIR423 FBN1 ACE
27 heart septal defect 30.4 TNNT2 TBX5 NPPA MYH6 MIR423 F2
28 pulmonary valve insufficiency 30.4 REN NPPB FBN1 CRP ACE
29 myocardial stunning 30.4 TNNT2 TNNI3 ACE
30 vascular disease 30.4 REN NPPB F2 CRP ALB ACE
31 end stage renal disease 30.4 REN NPPB CRP ALB ACE
32 acute kidney failure 30.4 REN NPPA F2 ALB
33 pericarditis 30.4 TNNT2 TNNI3 NPPB CRP ALB ACE
34 sick sinus syndrome 30.4 NPPA MYH6 MIR423 F2
35 congenitally corrected transposition of the great arteries 30.4 TNNT2 NPPB
36 first-degree atrioventricular block 30.4 NPPB CRP ACE
37 constrictive pericarditis 30.3 TNNI3 REN NPPB CRP ALB ACE
38 aortic disease 30.3 REN MYH11 MIR423 FBN1 CRP ACE
39 myocarditis 30.3 TNNI3 NPPB MYH6 ACE
40 carotid artery disease 30.3 REN CRP ACE
41 deficiency anemia 30.3 NPPA F2 CRP ALB ACE
42 hypertensive heart disease 30.3 REN NR3C2 NPPB NPPA ACE
43 kawasaki disease 30.2 NPPB CRP ALB
44 sleep apnea 30.2 REN NPPB CRP ALB ACE
45 pulmonary disease, chronic obstructive 30.2 NPPB MIR423 CRP ALB ACE
46 diastolic heart failure 30.2 TNNI3 REN NPPB NPPA MYBPC3 ACE
47 hypertrophic cardiomyopathy 30.2 TNNT2 TNNI3 REN NR3C2 NPPB NPPA
48 splenic infarction 30.1 F2 CRP ALB
49 uremia 30.1 REN CRP ALB ACE
50 moyamoya disease 1 30.1 MYH11 F2 CRP

Graphical network of the top 20 diseases related to Mitral Valve Insufficiency:



Diseases related to Mitral Valve Insufficiency

Symptoms & Phenotypes for Mitral Valve Insufficiency

MGI Mouse Phenotypes related to Mitral Valve Insufficiency:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10 ACE ALB CRP F2 FBN1 MYBPC3
2 homeostasis/metabolism MP:0005376 9.8 ACE ALB CKB CRP F2 FBN1
3 muscle MP:0005369 9.4 ALB F2 FBN1 MYBPC3 MYH11 MYH6

Drugs & Therapeutics for Mitral Valve Insufficiency

Drugs for Mitral Valve Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
2
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
5
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
6
Cosyntropin Approved Phase 4 16960-16-0 16129617
7
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
8
Etomidate Approved Phase 4 33125-97-2 36339 667484
9
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
10
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
11
Hydralazine Approved Phase 4 86-54-4 3637
12
Candesartan Experimental Phase 4 139481-59-7 2541
13 Sodium Channel Blockers Phase 4
14
protease inhibitors Phase 4
15 HIV Protease Inhibitors Phase 4
16 Serine Proteinase Inhibitors Phase 4
17 Anticoagulants Phase 4
18 Antithrombin III Phase 4
19 Antithrombins Phase 4
20 Omega 3 Fatty Acid Phase 4
21 Antioxidants Phase 4
22 Adrenergic beta-Antagonists Phase 4
23 Angiotensin Receptor Antagonists Phase 4
24 Giapreza Phase 4
25 Angiotensin II Type 1 Receptor Blockers Phase 4
26 Angiotensinogen Phase 4
27 Adrenergic Antagonists Phase 4
28 Adrenergic Agents Phase 4
29 Calamus Phase 4
30 Vasoconstrictor Agents Phase 4
31 Neurotransmitter Agents Phase 4
32 Anti-Arrhythmia Agents Phase 4
33 Sympatholytics Phase 4
34 Adrenergic beta-1 Receptor Antagonists Phase 4
35 Hormone Antagonists Phase 4
36 Anti-Inflammatory Agents Phase 4
37 Hormones Phase 4
38 Hypnotics and Sedatives Phase 4
39 Anesthetics, Intravenous Phase 4
40 Hydrocortisone hemisuccinate Phase 4
41 Hydrocortisone 17-butyrate 21-propionate Phase 4
42 Anesthetics, General Phase 4
43 Mineralocorticoids Phase 4
44 LCZ 696 Phase 4
45 Mineralocorticoid Receptor Antagonists Phase 4
46 Anesthetics Phase 4
47
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
48
Milrinone Approved Phase 3 78415-72-2 4197
49
Bupivacaine Approved, Investigational Phase 3 2180-92-9, 38396-39-3 2474
50
Nifedipine Approved Phase 3 21829-25-4 4485

Interventional clinical trials:

(show top 50) (show all 301)
# Name Status NCT ID Phase Drugs
1 The Effect of Different Surgical Methods in the Treatment of Patients With Ischemic Mitral Regurgitation and Assess the Dynamics of Heart Failure and the Effectiveness of Surgical Treatment of Mitral Valve. Unknown status NCT01368575 Phase 4
2 Interventional Strategy to Abrogate Mitral Regurgitation Using the MitraClip System in High-Risk Patients Considered Unsuitable for Surgery (ISAR-CLIP) Unknown status NCT01431222 Phase 4
3 (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Unknown status NCT02592889 Phase 4
4 Ranolazine Effects on Ischemic Mitral Regurgitation Severity in Patients With Cardiac Resynchronization Therapy Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
5 Effects of the Administration Of Antithrombin on the Coagulation Status and on the Inflammatory Response in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery Unknown status NCT01201070 Phase 4 antithrombin III
6 Mitigating Cardiac Inflammation and Oxidative Stress in Atrial Myocardium Via Short-term Lovaza Treatment Prior to Surgery Unknown status NCT01046604 Phase 4 Lovaza group
7 Multicenter, Randomized, Double-blind, Active-controlled Study to Assess the Efficacy of LCZ696 Compared to Valsartan on Reduction of Mitral Regurgitation in Patients With Left Ventricular Dysfunction and Secondary Functional Mitral Regurgitation of Stage B and C Completed NCT02687932 Phase 4 LCZ696;Valsartan
8 Angiotensin-II Blockade in Mitral Regurgitation Completed NCT00587470 Phase 4 Candesartan;atacand;Placebo
9 Beta Blockade in Mitral Regurgitation Completed NCT00166400 Phase 4 metoprolol succinate
10 Colvin-Galloway Future® Annuloplasty Ring/Band Clinical Trial: Interventional Multi-center Prospective Clinical Outcome Study Completed NCT01074671 Phase 4
11 Study of Paravertebral Block for Cardiac Surgery Completed NCT02180893 Phase 4
12 Effect of an Anesthetic Induction Dose of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery Completed NCT00415701 Phase 4 Etomidate;Propofol;Hydrocortisone;NaCl 0.9%
13 Clinical and Ultramicroscopic Myocardial Randomized Study of On-Pump Beating Heart Mitral Valve Replacement Completed NCT01641614 Phase 4
14 Survival of Patients With Primary Prophylactic ICD Indication, Provided With Intensified Care After 1st ICD Therapy Completed NCT00619593 Phase 4
15 The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation Recruiting NCT04217135 Phase 4 evidence-based medications vs. high-dose hydralazine + evidence-based medications
16 High and Intermediate Risk Degenerative Mitral Regurgitation Treatment: A Randomized Controlled Trial Comparing MitraClip® to Surgical Therapy Terminated NCT02534155 Phase 4
17 Multicentre Randomized Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation. Unknown status NCT01920698 Phase 3
18 Comparative Effects of Brief Inhaled Milrinone Versus Intravenous Milrinone on Pulmonary Arterial Pressure in Patients Undergoing Mitral Valve Surgery Completed NCT01621971 Phase 3 inhaled milrinone;intravenous milrinone
19 Randomized Evaluation of Mitral Annuloplasty During Coronary Artery Bypass Grafting for Moderate Functional Ischaemic Mitral Regurgitation. Completed NCT00413998 Phase 3
20 Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease) Completed NCT01052428 Phase 2, Phase 3 metoprolol succinate (Toprol XL);Placebo
21 Clinical Investigation Of The Sorin 3D Annuloplasty Ring For Mitral Repair Completed NCT00567853 Phase 3
22 Postoperative Analgesia After Cardiac Surgery - A Double-Blind, Prospective and Randomized Comparison of Wound Infiltration With Liposomal Bupivacaine and Bupivacaine Hydrochloride Completed NCT03270514 Phase 3 Exparel Injectable Product;Bupivacaine Hydrochloride
23 Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy of Ertugliflozin on Reduction of Mitral Regurgitation in Patients With Functional Mitral Regurgitation Secondary to Left Ventricular Dysfunction Recruiting NCT04231331 Phase 3 Ertugliflozin;Placebo
24 The Safety and Effectiveness of the SAPIEN 3 and SAPIEN 3 Ultra Valve in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification Who Are Not Candidates for Standard Mitral Valve Surgery. Recruiting NCT04408430 Phase 2, Phase 3
25 Safety and Efficacy of Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients With Heart Failure Suspended NCT00815386 Phase 2, Phase 3
26 Surgery Versus Medical Treatment Alone for Patients With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure: SMMART-HF Terminated NCT00608140 Phase 3 Optimal medical therapy (OMT)
27 Trial of ACE Inhibition in Children With Mitral Regurgitation After Repair of AVSD Terminated NCT00113698 Phase 3 Enalapril
28 Dynamic Annuloplasty System With Activation for the Treatment of Mitral Regurgitation Unknown status NCT00833014 Phase 2
29 Valtech Cardinal Adjustable Semi-Rigid Annuloplasty Ring System For Treatment of Mitral Valve Regurgitation in Open Surgical Repair Completed NCT01137734 Phase 2
30 Evaluation of Outcomes Following Mitral Valve Repair/Replacement in Severe Chronic Ischemic Mitral Regurgitation Completed NCT00807040 Phase 2
31 Surgical Ablation Versus No Surgical Ablation for Patients With Persistent or Longstanding Persistent Atrial Fibrillation (AF) Undergoing Mitral Valve Surgery Completed NCT00903370 Phase 2
32 An Open-Label, Single-Arm Pilot Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device Used to Reduce Mitral Regurgitation Completed NCT00572091 Phase 1, Phase 2
33 A Study of the Evalve Cardiovascular Valve Repair System Endovascular Valve Edge-to-Edge REpair STudy (EVEREST I). Completed NCT00209339 Phase 1, Phase 2
34 Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery Completed NCT00082121 Phase 2 TP10
35 Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve (RESTOR-MV) Completed NCT00120276 Phase 2
36 Evaluating the Severity of Mitral Regurgitation Using Phenylephrine During Transesophageal Echocardiography Recruiting NCT04500899 Phase 1, Phase 2 Mydfrin
37 A Multi-center Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients With Heart Failure Suspended NCT00787293 Phase 2
38 V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse Terminated NCT01415947 Phase 2
39 Mitral Valve Reconstruction in Patients With Chronic Heart Failure and Secondary Mitral Insufficiency: Identification of Predictors for a Successful Therapy Terminated NCT00348829 Phase 2
40 The RELIEF Trial: REduction or eLimination of mItral rEgurgitation in Degenerative or Functional Mitral Regurgitation With the CardiAQ-Edwards™ Transcatheter Mitral Valve Withdrawn NCT02722551 Phase 1, Phase 2
41 Medical Versus Surgical Management of Patients With Moderate Mitral Regurgitation Following Percutaneous Coronary Intervention for Myocardial Infarction: A Pilot Prospective Randomized Trial Withdrawn NCT01156441 Phase 1, Phase 2
42 Prospective.Randomized, Blinded, Crossover Chronic IDE Study of the Effects of Pacing on Mitral Regurgitation in Patients Without Standard Indications for Cardiac Resynchronization Therapy Unknown status NCT01242397 Phase 1
43 Valvular and Ventricular Improvement Via iCoapsys Delivery (VIVID) Feasibility Study Unknown status NCT00512005 Phase 1
44 Surgical Ablation of Ganglion Plexuses of the Pulmonary Artery in Patients With Valvular Heart Disease, Complicated by High Pulmonary Hypertension May Reduce Its Degree. Unknown status NCT02374229 Phase 1
45 An Open-Label, Single-Arm Feasibility Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty (PTMA) Device Used to Reduce Mitral Regurgitation. Completed NCT00568230 Phase 1
46 A Single-Center, Open-Label, Single-Arm Pilot Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Implantable Device Used to Reduce Mitral Valve Regurgitation. Completed NCT00571610 Phase 1
47 A Novel Adjustable Neochordae Technique in Mitral Valve Repair Not yet recruiting NCT04299334 Phase 1
48 Beta-Blockade in Chronic Mitral Regurgitation: Moving From the Laboratory Experiment to Clinical Investigation Terminated NCT00700947 Phase 1 Beta-blocker therapy (TOPROL-XL® )
49 Individualized Surgical Repair for Congenital Mitral Insufficiency in Infants and Children Unknown status NCT03567668
50 Predictors of Postoperative Left Ventricular Function in Patients Undergoing Mitral Valve Repair for Severe Degenerative Mitral Regurgitation Unknown status NCT01519050

Search NIH Clinical Center for Mitral Valve Insufficiency

Cochrane evidence based reviews: mitral valve insufficiency

Genetic Tests for Mitral Valve Insufficiency

Genetic tests related to Mitral Valve Insufficiency:

# Genetic test Affiliating Genes
1 Mitral Regurgitation 29

Anatomical Context for Mitral Valve Insufficiency

MalaCards organs/tissues related to Mitral Valve Insufficiency:

40
Heart, Brain, Kidney, Endothelial, Bone, Lymph Node, Thyroid

Publications for Mitral Valve Insufficiency

Articles related to Mitral Valve Insufficiency:

(show top 50) (show all 15756)
# Title Authors PMID Year
1
A Screening Approach to Identify Clinically Actionable Variants Causing Congenital Heart Disease in Exome Data. 6
29555671 2018
2
Relationship between the tissue Doppler-derived Tei index and plasma brain natriuretic peptide levels in patients with mitral regurgitation. 54 61
20329488 2010
3
Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. 54 61
19996017 2009
4
Tei index correlates with tissue Doppler parameters and reflects neurohormonal activation in patients with an abnormal transmitral flow pattern. 61 54
19558518 2009
5
BNP in mitral valve restrictive annuloplasty for ischemic mitral regurgitation. 61 54
18657328 2009
6
Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. 61 54
19744620 2009
7
Decline of plasma brain natriuretic peptide during enzyme replacement therapy in a female patient with heterozygous Fabry's disease. 54 61
19282651 2009
8
Successful catheter ablation to accessory atrioventricular pathway as cardiac resynchronization therapy in a patient with dilated cardiomyopathy. 54 61
19028709 2009
9
Predictors of mortality from pump failure and sudden cardiac death in patients with systolic heart failure and left ventricular dyssynchrony: results of the CARE-HF trial. 61 54
18926439 2008
10
Dynamic left ventricular dyssynchrony contributes to B-type natriuretic peptide release during exercise in patients with systolic heart failure. 61 54
18319268 2008
11
Correlation of the myocardial performance index with plasma B-type natriuretic peptide levels in patients with mitral regurgitation. 54 61
17541723 2008
12
Elevated B-type natriuretic peptide despite normal left ventricular function on rest and exercise stress echocardiography in mitral regurgitation. 61 54
18202251 2008
13
The combination of B-type natriuretic peptide and C-reactive protein provides incremental prognostic value among older patients referred for cardiac catheterization. 61 54
17617749 2007
14
Assessment of factors affecting plasma BNP levels in patients with chronic atrial fibrillation and preserved left ventricular systolic function. 54 61
16959341 2007
15
Usefulness of the brain natriuretic peptide to atrial natriuretic peptide ratio in determining the severity of mitral regurgitation. 61 54
17380223 2007
16
Significance of brain natriuretic peptide in the evaluation of symptoms and the degree of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. 54 61
17243506 2006
17
Predictors of remodeling in the CRT era: influence of mitral regurgitation, BNP, and gender. 61 54
16624682 2006
18
Association of B-type natriuretic peptide activation to left ventricular end-systolic remodeling in organic and functional mitral regurgitation. 61 54
16563910 2006
19
Efficacy of nasal bi-level positive airway pressure in congestive heart failure patients with cheyne-stokes respiration and central sleep apnea. 54 61
16041159 2005
20
B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. 61 54
15883225 2005
21
Clinical applications of B-type natriuretic peptide levels in the care of cardiovascular patients. 61 54
15729209 2004
22
Changes in type B natriuretic peptide (BNP) concentrations during cardiac valve replacement. 61 54
15144992 2004
23
Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. 54 61
15013124 2004
24
[Autoantibodies: new upstream targets of paroxysmal atrial fibrillation in patients with congestive heart failure]. 61 54
12463096 2002
25
Atrial natriuretic factor and mitral valve prolapse syndrome. 61 54
11533551 2001
26
Acute mitral regurgitation due to chordal rupture in a patient with neonatal Marfan syndrome caused by a deletion in exon 29 of the FBN1 gene. 61 54
10441700 1999
27
Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure. 54 61
10379945 1999
28
Hemodynamic correlates of atrial natriuretic peptide concentration in unselected patients with heart disease of different etiologies. 61 54
9887389 1998
29
Effect of continuous positive airway pressure on mitral regurgitant fraction and atrial natriuretic peptide in patients with heart failure. 61 54
9283534 1997
30
Associations between atrial natriuretic peptides, echocardiographic findings and mortality in an elderly population sample. 61 54
9159597 1997
31
Plasma atrial natriuretic peptide is elevated in patients with hypertrophic cardiomyopathy. 54 61
8842784 1996
32
Ventricular adenine nucleotide translocator mRNA is upregulated in dilated cardiomyopathy. 54 61
8252591 1993
33
A new and rare form of Williams' syndrome. 54 61
8351994 1993
34
[Correlations between plasma concentrations of atrial natriuretic factor and right ventricular function in patients with severe cardiac failure]. 54 61
1532302 1992
35
Dynamics of creatine kinase shuttle enzymes in the human heart. 61 54
1909638 1991
36
[Supravalvular aortic stenosis syndrome with advanced mitral regurgitation requiring extended aortoplasty and mitral valve replacement: a case report]. 54 61
2038171 1991
37
A Narrative Review for Cardiac Anesthesiologists of the 2019 Expert Consensus on Operator and Institutional Recommendations for Transcatheter Mitral Valve Intervention. 61
33376071 2021
38
Prognostic utility of the assessment of diastolic function in patients undergoing cardiac resynchronization therapy. 61
33535079 2021
39
Standard and emerging CMR methods for mitral regurgitation quantification. 61
33548381 2021
40
Acute Severe Functional Mitral Regurgitation After Non-Mitral Valve Cardiac Surgery-Left Ventricular Dyssynchrony as a Potential Mechanism. 61
32921604 2021
41
Value of a comprehensive exercise echocardiography assessment for patients with hypertrophic cardiomyopathy. 61
33341337 2021
42
Long-term Clinical Impacts of Functional Mitral Stenosis After Mitral Valve Repair. 61
32980324 2021
43
Paravalvular leak closure: Still a challenge with unpredictable results. 61
33648808 2021
44
Current status of the treatment of degenerative mitral valve regurgitation. 61
33745777 2021
45
Changes in cardiac sympathetic nerve activity on 123 I-metaiodobenzylguanidine scintigraphy after MitraClip therapy. 61
33609015 2021
46
Two-in-one: A case report of a touchy TAVI procedure with a new valve. 61
33616253 2021
47
Transpericardial 3D Echocardiography in the Sheep Model, Facilitating Real Time Anatomical Assessment for Planning and Guiding Transcatheter Mitral Valve Replacement and Repair. 61
33263928 2021
48
Robotic versus port-access mitral repair: A propensity score analysis. 61
33462900 2021
49
Mitral valve repair rates in degenerative mitral valve disease correlate with surgeon and hospital procedural volume. 61
33616240 2021
50
"Learning curve and procedural volume in mitral valve disease". 61
33616264 2021

Variations for Mitral Valve Insufficiency

ClinVar genetic disease variations for Mitral Valve Insufficiency:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TBX5 NM_000192.3(TBX5):c.1221C>G (p.Tyr407Ter) SNV Pathogenic 495227 rs1555223259 GRCh37: 12:114793673-114793673
GRCh38: 12:114355868-114355868
2 FBN1 NM_000138.4(FBN1):c.8016T>G (p.Cys2672Trp) SNV Likely pathogenic 374081 rs1057518883 GRCh37: 15:48707768-48707768
GRCh38: 15:48415571-48415571
3 FBN1 NM_000138.4(FBN1):c.478T>C (p.Cys160Arg) SNV Likely pathogenic 374203 rs1057518973 GRCh37: 15:48888540-48888540
GRCh38: 15:48596343-48596343
4 MYH11 , NDE1 NM_002474.3(MYH11):c.4360G>C (p.Asp1454His) SNV Likely pathogenic 374162 rs1057518938 GRCh37: 16:15818023-15818023
GRCh38: 16:15724166-15724166

Expression for Mitral Valve Insufficiency

Search GEO for disease gene expression data for Mitral Valve Insufficiency.

Pathways for Mitral Valve Insufficiency

Pathways related to Mitral Valve Insufficiency according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.27 TNNT2 TNNI3 NPPB NPPA MYH6
2
Show member pathways
12.23 TNNT2 TNNI3 TBX5 NPPA MYH6 MYH11
3
Show member pathways
11.82 TNNT2 TNNI3 MYH6 MYBPC3 ACE
4 11.75 TNNT2 TNNI3 TBX5 ALB
5 11.63 TNNT2 TNNI3 TBX5
6 11.57 TNNT2 TNNI3 MYH6
7
Show member pathways
11.51 REN NR3C2 ACE
8 11.42 REN NPPA ACE
9 11.42 TNNT2 TNNI3 MYH6 MYBPC3
10 10.65 TNNT2 TNNI3 TBX5 MYH6

GO Terms for Mitral Valve Insufficiency

Cellular components related to Mitral Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.09 REN NPPB NPPA LYPD4 FBN1 F2
2 extracellular space GO:0005615 9.96 REN NPPB NPPA MIR423 FBN1 F2
3 myofibril GO:0030016 9.54 TNNT2 TNNI3 MYH6
4 troponin complex GO:0005861 9.4 TNNT2 TNNI3
5 myosin filament GO:0032982 9.33 MYH6 MYH11 MYBPC3
6 cardiac Troponin complex GO:1990584 9.32 TNNT2 TNNI3
7 sarcomere GO:0030017 9.26 TNNT2 TNNI3 MYH6 MYBPC3
8 cardiac myofibril GO:0097512 8.8 TNNT2 TNNI3 MYBPC3

Biological processes related to Mitral Valve Insufficiency according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.71 NPPA FBN1 F2 ALB
2 muscle contraction GO:0006936 9.62 TNNT2 TNNI3 MYH6 MYH11
3 cardiac muscle contraction GO:0060048 9.56 TNNT2 TNNI3 MYH6 MYBPC3
4 amyloid-beta metabolic process GO:0050435 9.54 REN ACE
5 cardiac muscle hypertrophy in response to stress GO:0014898 9.52 NPPA MYH6
6 negative regulation of systemic arterial blood pressure GO:0003085 9.51 NPPB NPPA
7 negative regulation of ATPase activity GO:0032780 9.49 TNNT2 TNNI3
8 angiotensin maturation GO:0002003 9.48 REN ACE
9 cGMP biosynthetic process GO:0006182 9.46 NPPB NPPA
10 muscle filament sliding GO:0030049 9.46 TNNT2 TNNI3 MYH6 MYBPC3
11 receptor guanylyl cyclase signaling pathway GO:0007168 9.43 NPPB NPPA
12 cardiac muscle fiber development GO:0048739 9.37 MYH6 MYH11
13 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.26 TNNT2 TNNI3 MYH6 MYBPC3
14 regulation of blood pressure GO:0008217 9.02 REN NPPB NPPA MYH6 ACE

Molecular functions related to Mitral Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone receptor binding GO:0051427 9.16 NPPB NPPA
2 actin binding GO:0003779 9.1 TNNT2 TNNI3 MYH6 MYH11 MYBPC3 ACE
3 troponin C binding GO:0030172 8.96 TNNT2 TNNI3

Sources for Mitral Valve Insufficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....